Junctin Inhibitors
Junctin inhibitors represent a class of chemical compounds that target the protein junctin, which is integral to calcium handling within the sarcoplasmic reticulum (SR) of muscle cells, particularly in the heart and skeletal muscles. Junctin is a key component of the macromolecular complex that includes ryanodine receptors (RyR), calsequestrin (CSQ), and triadin. These proteins collectively regulate calcium storage and release during muscle contraction and relaxation. Junctin's role in modulating calcium dynamics involves its ability to interact with both CSQ and RyR, controlling the release of calcium from the SR into the cytoplasm. This release is crucial for the initiation of muscle contraction. By inhibiting junctin, compounds in this class affect the homeostasis of intracellular calcium, influencing the balance of calcium uptake and release in muscle cells, which can alter the contractile responses of these tissues.
Chemically, junctin inhibitors are designed to disrupt the interactions between junctin and its associated proteins, thereby modifying the function of the ryanodine receptor complex. This disruption can be achieved through different mechanisms, such as direct binding to junctin, altering its conformation, or affecting its localization within the SR. These inhibitors often exhibit specificity for junctin without affecting other proteins in the calcium-handling complex, although the precise mechanisms of action may vary among different inhibitors. By influencing calcium fluxes in muscle cells, junctin inhibitors serve as valuable tools for studying the molecular mechanisms of calcium regulation, providing insights into how alterations in junctin activity can influence muscle physiology, including contraction and relaxation processes.
SEE ALSO...
Items 1 to 10 of 13 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This DNA methyltransferase inhibitor may lead to the demethylation of the junctin gene promoter, potentially resulting in decreased transcription of the junctin gene. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
As a histone deacetylase inhibitor, Trichostatin A could cause increased acetylation of histones near the junctin gene, which may result in reduced junctin protein expression due to altered chromatin conformation. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
This antibiotic binds to DNA and obstructs the elongation phase of RNA polymerase, which could diminish junctin mRNA synthesis and consequently lower junctin protein levels. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
By inhibiting the translocation step in protein synthesis, Cycloheximide could lead to a broad decrease in protein production, including a reduction in the synthesis of the junctin protein. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
This mTOR inhibitor may downregulate the translation of many proteins by inhibiting mTORC1, potentially leading to decreased synthesis of the junctin protein. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
This MEK1/2 inhibitor may decrease ERK pathway signaling, potentially leading to reduced transcription of genes, including those coding for junctin. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
By inhibiting p38 MAPK, SB 203580 could disrupt downstream signaling that may be necessary for the transcription of the junctin gene, thereby reducing junctin expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
This phosphatidylinositol 3-kinase (PI3K) inhibitor could decrease the activity of the PI3K/Akt pathway, possibly leading to a decrease in the synthesis of proteins such as junctin. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
By inhibiting JNK, SP600125 could reduce the activity of transcription factors that control the expression of the junctin gene, possibly resulting in lower junctin protein levels. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This MEK inhibitor could reduce ERK signaling, potentially leading to downregulated transcription of the junctin gene and reduced protein expression. | ||||||